A growing volume of combination products, particularly for cutting-edge gene and cellular therapies and other new medical technologies, is creating challenges for FDA s Office of Combination Products (OCP) and its role in advising on whether a new combination therapy should be designated as a drOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.